Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Short-Term Debt issuances (2016 - 2024)

Cumberland Pharmaceuticals (CPIX) has disclosed Short-Term Debt issuances for 12 consecutive years, with $5.5 million as the latest value for Q4 2024.

  • Quarterly Short-Term Debt issuances fell 28.57% to $5.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Sep 2025, down 86.48% year-over-year, with the annual reading at $38.5 million for FY2024, 22.28% up from the prior year.
  • Short-Term Debt issuances hit $5.5 million in Q4 2024 for Cumberland Pharmaceuticals, down from $11.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $20.0 million in Q1 2022 to a low of $5.5 million in Q4 2024.
  • Historically, Short-Term Debt issuances has averaged $12.0 million across 5 years, with a median of $11.0 million in 2024.
  • Biggest five-year swings in Short-Term Debt issuances: soared 88.24% in 2021 and later plummeted 60.0% in 2023.
  • Year by year, Short-Term Debt issuances stood at $15.0 million in 2020, then fell by 6.67% to $14.0 million in 2021, then plummeted by 55.71% to $6.2 million in 2022, then increased by 24.19% to $7.7 million in 2023, then dropped by 28.57% to $5.5 million in 2024.
  • Business Quant data shows Short-Term Debt issuances for CPIX at $5.5 million in Q4 2024, $11.0 million in Q3 2024, and $11.0 million in Q2 2024.